

## 9.4 References

- 1 General Medical Council. Good Medical Practice. General Medical Council, London 2001.
- 2 World Health Organization. World Malaria Report 2005. Geneva 2005.
- 3 White NJ. Manson's Tropical Diseases. Cook, G. C. & Zumla, A. (eds.), pp. 1242-8 Elsevier Science 2003.
- 4 Hay SI, Guerra CA, Tatem AJ, Atkinson PM, Snow RW. Urbanization, malaria transmission and disease burden in Africa. *Nat Rev Microbiol.* 2005;3:81-90.
- 5 Sharma VP. Current scenario of malaria in India. *Parassitologia.* 1999;41:349-53.
- 6 Maguire JD, Sumawinata IW, Masbar S *et al.* Chloroquine-resistant *Plasmodium malariae* in south Sumatra, Indonesia. *Lancet.* 2002;360:58-60.
- 7 Montemarano AD, Gupta RK, Burge JR, Klein K. Insect repellents and the efficacy of sunscreens. *Lancet.* 1997;349: 1670-1.
- 8 Murphy ME, Montemarano AD, Debboun M, Gupta R. The effect of sunscreen on the efficacy of insect repellent: a clinical trial. *Journal American of the Academy of Dermatology.* 2000;43:219-22.
- 9 McGready R, Hamilton KA, Simpson JA *et al.* Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy. *American Journal of Tropical Medicine & Hygiene.* 2001;65:285-9.
- 10 Govere J, Durrheim DN, Baker L, Hunt R, Coetzee M. Efficacy of three insect repellents against the malaria vector *Anopheles arabiensis*. *Medical & Veterinary Entomology.* 2000;14:441-4.
- 11 Canadian recommendations for the prevention and treatment of malaria among international travellers. Canadian Communicable Disease Report. 2004;30 (Suppl 1):1-62.
- 12 Badolo A, Ilboudo-Sanogo E, Ouedraogo AP, Costantini C. Evaluation of the sensitivity of *Aedes aegypti* and *Anopheles gambiae* complex mosquitoes to two insect repellents: DEET and KBR 3023. *Tropical Medicine International Health.* 2004;9:330-4.
- 13 Costantini C, Badolo A, Ilboudo-Sanogo E. Field evaluation of the efficacy and persistence of insect repellents DEET, IR3535, and KBR 3023 against *Anopheles gambiae* complex and other Afrotropical vector mosquitoes. *Transactions of the Royal Society of Tropical Medicine & Hygiene.* 2004;98:644-52.
- 14 World Health Organization. Report of the fourth WHOPES working group meeting. WHO/CDS/WHOPES/2001.2. 2001. Geneva, World Health Organization.
- 15 No authors listed. Picardin-a new insect repellent. *Medical Letters Drugs Therapy.* 2005;47:46-7.

- 16 Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. *New England Journal of Medicine*. 2002;347:13-18.
- 17 Petersen E. Malaria chemoprophylaxis: when should we use it and what are the options? *Expert Review Anti-Infective Therapy*. 2004;2:119-32.
- 18 Lines JD, Myamba J, Curtis C F. Experimental hut trials of permethrin-impregnated mosquito nets and eave curtains against malaria vectors in Tanzania. *Medical & Veterinary Entomology*. 1987;1:37-51.
- 19 Schreck CE, Carlson DA, Weidhass DE. Wear and ageing tests with permethrin treated cotton polyester fabric. *Journal of Economic Entomology*. 1980;73:541-3.
- 20 Hewitt SE, Farham M, Urhaman H, Muhammed N, Kamal M, Rowland MW. Self-protection from malaria vectors in Pakistan: an evaluation of popular existing methods and appropriate new techniques in Afghan refugee communities. *Annual Tropical Medicine & Parasitology*. 1996; 90:337-44.
- 21 Khan AA, Maibach HI, Strauss WG, Fenley WR. Vitamin B1 is not a systemic mosquito repellent in man. *Transactions of the St. Johns Hospital Dermatological Society*. 1969;55: 99-102.
- 22 Ives AR, Paskewitz SM. Testing vitamin B as a home remedy against mosquitoes. *Journal of the American Mosquito Control Association*. 2005;21:213-7.
- 23 Rajan TV, Hein M, Porte P, Wikel S. A double-blinded, placebo-controlled trial of garlic as a mosquito repellent: a preliminary study. *Medical & Veterinary Entomology*. 2005;19: 84-9.
- 24 Dondorp AM, Newton PN, Mayxay M *et al*. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. *Tropical Medicine International Health*. 2004;9:1241-6.
- 25 Chulay JD. Challenges in the development of antimalarial drugs with causal prophylactic activity. *Transactions of the Royal Society Of Tropical Medicine & Hygiene*. 1998;92:577-9.
- 26 Franco-Paredes C, Santos-Preciado JI. Problem pathogens: prevention of malaria in travellers. *Lancet Infectious Disease*. 2006; 6:139-49.
- 27 Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. *American Journal of Tropical Medicine & Hygiene*. 2006;75: 402-15.
- 28 Pappaioanou M, Fishbein DB, Dreesen DW *et al*. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. *New England Journal of Medicine*. 1986;314:280-4.

- 29 Hill DR. Travel Associated Disease. Cook GC (ed.), p. 101 Royal College of Physicians, London,1995.
- 30 Limsomwong N, Pang LW, Singharaj P. Malaria prophylaxis with proguanil in children living in a malaria-endemic area. *American Journal of Tropical Medicine & Hygiene*. 1988;38:231-6.
- 31 Moore DA, Grant AD, Armstrong M, Stumpfle R, Behrens RH. Risk factors for malaria in UK travellers. *Transactions of the Royal Society of Tropical Medicine & Hygiene*. 2004;98:55-63.
- 32 Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. *Lancet Infectious Diseases*. 2002;2:209-18.
- 33 Schlagenhauf P, Tschopp A, Johnson R *et al*. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. *British Medical Journal*. 2003;327:1078.
- 34 Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. *Drug Safety*. 2004;27:203-13.
- 35 Wells TS, Smith TC, Smith B *et al*. Mefloquine use and hospitalizations among US service members, 2002-2004. *American Journal of Tropical Medicine & Hygiene*. 2006;74:744-9.
- 36 Taylor WR, White NJ. Antimalarial drug toxicity: a review. *Drug Safety*. 2004;27, 25-61.
- 37 Ohrt, C, Richie TL, Widjaja H *et al*. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine*. 1997;126:963-72.
- 38 Bryant SG, Fisher S, Kluge RM. Increased frequency of doxycycline side effects. *Pharmacotherapy*. 1987;7:125-9.
- 39 Edstein MD, Yeo AE, Kyle DE, Looareesuwan S, Wilairatana P, Rieckmann KH. Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro. *Transactions of the Royal Society of Tropical Medicine & Hygiene*. 1996;90:418-21.
- 40 Berman JD, Nielsen R, Chulay JD. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. *Transactions of the Royal Society of Tropical Medicine & Hygiene* . 2001;95:429-32.
- 41 Camus D, Djossou F, Schilthuis HJ *et al*. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. *Clinical Infectious Diseases*. 2004;38:1716-23.
- 42 Faucher JF, Binder R, Missinou MA *et al*. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. *Clinical Infectious Diseases*. 2002;35:1147-54.

- 43 Lell B, Luckner D, Ndjave M, Scott T, Kreamer PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. *Lancet*. 1998;351:709-13.
- 44 Ling J, Baird JK, Fryauff DJ *et al*. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of *Plasmodium falciparum* or *Plasmodium vivax* malaria among migrants to Papua, Indonesia. *Clinical Infectious Diseases*. 2002;35:825-33.
- 45 Marra F, Salzman JR, Ensom MH. Atovaquone-proguanil for prophylaxis and treatment of malaria. *Annals of Pharmacotherapy*. 2003;37:1266-75.
- 46 Overbosch D, Schilthuis H, Bienzle U *et al*. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. *Clinical Infectious Diseases*. 2001;33:1015-21.
- 47 Shanks GD, Gordon DM, Klotz FW *et al*. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for *Plasmodium falciparum* malaria. *Clinical Infectious Diseases*. 1998;27:494-9.
- 48 Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. *American Journal of Tropical Medicine & Hygiene*. 1999;60:521-5.
- 49 Soto J, Toledo J, Luzz M, Gutierrez P, Berman J, Duparc S. Randomized, double-blind, placebo-controlled study of Malarone for malaria prophylaxis in non-immune Colombian soldiers. *American Journal of Tropical Medicine & Hygiene*. 2006;75:430-3.
- 50 Chen LH, Keystone JS. New strategies for the prevention of malaria in travelers. *Infectious Disease Clinics of North America*. 2005;19:185-210.
- 51 World Health Organization International travel and health. World Health Organization, Geneva, 2005.
- 52 Touze JE, Heno P, Fourcade L *et al*. The effects of antimalarial drugs on ventricular repolarization. *American Journal of Tropical Medicine & Hygiene*. 2002;67:54-60.
- 53 World Health Organization. The use of malaria rapid diagnostic tests. 2004. World Health Organization.
- 54 Jelinek T, Grobusch MP, Nothdurft HD. Use of dipstick tests for the rapid diagnosis of malaria in nonimmune travelers. *Journal of Travel Medicine*. 2000;7:175-9.
- 55 Hughes C, Tucker R, Bannister B, Bradley DJ. Malaria prophylaxis for long-term travellers. *Communicable Disease & Public Health*. 2003;6:200-208.

- 56 Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. *American Journal of Tropical Medicine & Hygiene*. 1996;55(1 Suppl):50-56.
- 57 Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A, Chongsuphajaisiddhi T, White NJ. The effects of mefloquine treatment in pregnancy. *Clinical Infectious Diseases*. 1999;28:808-15.
- 58 Armstrong G, Beg MF, Scahill S. Warfarin potentiated by proguanil. *British Medical Journal*. 1991;303:789.
- 59 Joint Formulary Committee British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. London, 2006.
- 60 Leon MN, Lateef M, Fuentes F. Prevention and Management of Cardiovascular Events during Travel. *Journal of Travel Medicine*. 1996;3:227-30.
- 61 Saunders MA, Hammer MF, Nachman MW. Nucleotide variability at G6PD and the signature of malarial selection in humans. *Genetics*. 2002;162:1849-61.
- 62 Serjeant GR. Infections in Sickle Cell Disease. In Cohen, J. & Powderly, WG (eds.) *Infectious Diseases*. p.1618. Mosby, Edinburgh, 2004.
- 63 Kotton CN, Ryan ET, Fishman JA. Prevention of infection in adult travelers after solid organ transplantation. *American Journal of Transplantation*. 2005;5:8-14.
- 64 Kamya MR, Gasasira AF, Yeka A *et al*. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. *Journal of Infectious Diseases*. 2006;193:9-15.
- 65 Korenromp EL, Williams BG, de Vlas SJ *et al*. Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. *Emerging Infectious Diseases*. 2005;11:1410-19.
- 66 World Health Organization. Standards for maternal and neonatal care. 2004. World Health Organisation.
- 67 Health Protection Agency. Migrant Health: Infectious diseases in non-UK born populations in England, Wales and Northern Ireland. A baseline report – 2006. London: Health Protection Agency Centre for Infections. 2006.
- 68 Stenbeck JL. Health hazards in Swedish field personnel in the tropics. *Travel Medicine International*. 1991;9:51-9. 68. 69. Schneider I, Bradley DJ. 2003. Unpublished work.
- 70 Steffen R, Heusser R, Machler R *et al*. Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy. *Bulletin of the World Health Organization*. 1990;68:313-22.
- 71 Janosi M. Advice to long-term travellers. *Travel Medicine International*. 1998;6:110-12.

- 72 Lobel HO, Phillips-Howard PA, Brandling-Bennett AD *et al.* Malaria incidence and prevention among European and north American travellers to Kenya. *Bulletin of the World Health Organization.* 1990;68:209-15.
- 73 Bruce-Chwatt LJ, Bruce-Chwatt JM. Antimalarial drugs in West Africa, with particular reference to proguanil; results of a survey in Nigeria. *British Medical Journal.* 1950;2:7-14.
- 74 Luxemburger C, Price RN, Nosten F, Ter Kuile FO, Chongsuphajaisiddhi T, White NJ. Mefloquine in infants and young children. *Annals of Tropical Paediatrics.* 1996;16:281-286.
- 75 Hopperus Buma AP, van Thiel PP, Lobel HO *et al.* Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. *Journal of Infectious Diseases.* 1996;173:1506-9.
- 76 Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC. Long-term malaria prophylaxis with weekly mefloquine. *Lancet.* 1993;341:848-51.
- 77 Peragallo MS, Sabatinelli G, Sarnicola G. Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military). *Transactions of the Royal Society of Tropical Medicine & Hygiene.* 1999;93:73-7.
- 78 Delaney TJ, Leppard BJ, MacDonald DM. Effects of long term treatment with tetracycline. *Acta dermatovenereologica.* 1974;54:487-9.
- 79 World Health Organization Factsheet No. 94 Malaria  
[http://www.rbm.who.int/cmc\\_upload/0/000/015/369/RBMInfosheet\\_4.htm](http://www.rbm.who.int/cmc_upload/0/000/015/369/RBMInfosheet_4.htm)  
(accessed 15 Nov 2006)
- 80 Luzzi GA, Peto TE. Adverse effects of antimalarials. An update. *Drug Safety.* 1993;8:295-311.
- 81 Lange WR, Frankenfield DL, Moriarty-Sheehan M, Contoreggi CS, Frame JD. No evidence for chloroquine-associated retinopathy among missionaries on long-term malaria chemoprophylaxis. *American Journal of Tropical Medicine & Hygiene.* 1994;51:389-92.
- 82 Overbosch D. Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. *Journal of Travel Medicine.* 2003;10(Suppl 1):S16-S20.